CLINICAL TRIALS PROFILE FOR ECOPIPAM

Clinical Trials for Ecopipam

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01065558 ↗	Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease	Completed	Psyadon Pharma	Phase 1	The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its family of receptors (i.e, the D1 family). LND is a very rare genetic disease. The sponsor is doing this study to find out what side effects ecopipam causes in LND patients, and whether ecopipam may be able to relieve the self-injurious behaviors seen in these patients.
NCT01215357 ↗	Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble	Completed	Psyadon Pharma	Phase 2	This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
NCT01244633 ↗	Ecopipam Treatment of Tourette Syndrome	Completed	Psyadon Pharma	Phase 1/Phase 2	Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
NCT01408394 ↗	Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam	Completed	Psyadon Pharma	Phase 1	Ecopipam hydrochloride (HCl) is an investigational drug being studied for several possible diseases. To date, all clinical studies have been done using the ecopipam immediate release (IR) tablet. However, a controlled release (CR) capsule formulation of ecopipam has been produced that may be able to improve its effectiveness and reduce its side effects. The main purpose of this study is to evaluate the safety and tolerability of ecopipam CR capsules when given as single oral dose in healthy volunteers.
NCT01751802 ↗	Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease	Terminated	Psyadon Pharma	Phase 3	The purpose of this research study is to gather scientific information about the effectiveness and safety of the study drug, Ecopipam (PSYRX 101), for the treatment of self-injurious behaviors when compared with the effectiveness and safety of placebo (inactive substance) in subjects with Lesch-Nyhan Disease.

Clinical Trial Conditions for Ecopipam

Condition Name

Condition Name
Intervention	Trials
Drug Interaction	3
Lesch-Nyhan Disease	2
Tourette's Syndrome	2
Communication Disorder	1

Condition MeSH

Condition MeSH
Intervention	Trials
Tourette Syndrome	5
Syndrome	5
Childhood-Onset Fluency Disorder	2
Stuttering	2

Clinical Trial Locations for Ecopipam

Trials by Country

Trials by Country
Location	Trials
United States	85
Germany	6
Canada	5
France	4
Poland	2

Trials by US State

Trials by US State
Location	Trials
Florida	7
California	7
Texas	7
Georgia	6
New York	5

Clinical Trial Progress for Ecopipam

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2/Phase 3	1
Phase 2	5

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	6
Completed	6
Unknown status	3

Clinical Trial Sponsors for Ecopipam

Sponsor Name

Sponsor Name
Sponsor	Trials
Emalex Biosciences Inc.	10
Psyadon Pharma	6
Nuventra	3

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	20
Other	13